Enabling success in translational research
AYOXXA Biosystems GmbH is a venture-backed life science tools company driving advances that empower translational proteomics, setting sights on better diagnostics and therapeutics. Presently entering the commercial phase of growth, our company is an international and multidisciplinary team of scientists, technicians, engineers and business professionals working relentlessly to realize our vision of enabling success in translational proteomics.
Together, we have transformed an innovative technology exclusively licensed from the National University of Singapore in 2010, into a mature, groundbreaking protein analysis platform. Designed to deliver high-quality data on multiple proteins in the same small-volume sample, LUNARIS™ enables fully scalable quantitative validation of disease-relevant biomarkers: from lab to clinic – from model to man – from data to insight.
The Right Team to Fuel Breakthroughs
Headquartered in Cologne (Germany), the international footprint of AYOXXA includes commercial and research operations in Singapore and commercial operations in Boston (USA).
We are a young and energetic company, guided by an experienced leadership, and determined to create research tools that boost translational research. Beyond facilitating discoveries in the lab, our LUNARIS™ Technology is the optimal analysis platform for the pre-clinical and clinical development work that transforms those discoveries into novel diagnostics and therapies.
Dr. Markus Zumbansen
Institutional investors have made our work possible, but also private investors support our vision. These include a US investor, several of our employees, and some well-known and respected founders of important life sciences and biotechnology companies.
Investments are tax deductible, an incentive detailed in the INVEST program granted by BAFA of the German Federal Ministry for Economic Affairs and Energy.
AYOXXA operates within an extensive network of people and companies that have supported us from day one. We count on our collaborators in the biotech and life sciences industry for continuous exchange of insights, and validation of key strategic decisions before implementation.